Top Ten most popular articles on Pharmafile.com this week
pharmafile | June 12, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | coronavirus, top 10
The news this week continues to be dominated by breakthroughs in COVID-19 treatments, with a US clinical trial of the drug ivermectin finding that it reduced the mortality rate of COVID-19 patients by 40%, while an antibody therapy for coronavirus could be available from Eli Lilly as early as September, according to one of its chief scientists.
In other news, Janssen has revealed data from two Phase 3 trials for Tremfya, showing improvement in skin clearance and symptoms in adult patients with active psoriatic arthritis, while 26 pharmaceutical companies are being sued by most US states for allegedly conspiring to reduce competition and drive up generic drug prices.
1 – US trial of ivermectin cuts coronavirus mortality by 40%
A US clinical trial of the drug ivermectin found that it reduced the mortality rate of COVID-19 patients by 40%.
2 – Trump’s Operation Warp Speed selects Pfizer, Merck, AstraZeneca and Moderna as vaccine finalists
The Trump administration has selected the finalists for the COVID-19 vaccine it is seeking to make widely available by the end of the year.
Australia could be set to follow the decisions of other nations around the world in officially licensing Gilead’s antiviral therapy remdesivir in the treatment of COVID-19, after the country’s National COVID-19 Clinical Evidence Taskforce, a specialist team bringing together some of Australia’s leading health groups, has given its recommendation for routine use of the drug.
AstraZeneca has revealed more data in its efforts to find an effective therapy for those affected by the novel coronavirus. While the company has placed its primary efforts in the development of the University of Oxford’s vaccine candidate, known as AZD1222, it has now shed light on the possible efficacy of its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in the treatment of severe cases of COVID-19.
5 – Leading pharmaceutical companies sued in US for conspiring to drive up generics prices
26 pharmaceutical companies are being sued by most US states for allegedly conspiring to reduce competition and drive up generic drug prices.
6 – Eli Lilly’s coronavirus antibody treatments could be available by September
An antibody therapy for coronavirus could be available from Eli Lilly as early as September, according to one of its chief scientists.
Oxford Biomedica has forged a five-year partnership with the Vaccines Manufacturing and Innovation Centre (VMIC) to work together to provide manufacturing capacity for viral vector vaccines, particularly to tackle the ongoing COVID-19 crisis.
Janssen has revealed data from two Phase 3 trials for Tremfya (guselkumab), showing improvement in skin clearance and symptoms in adult patients with active psoriatic arthritis (PsA).
9 – EMA could approve Gilead’s streamlined remdesivir application for COVID-19 “within weeks”
The European Medicines Agency has received the application from Gilead for the first conditional marketing authorisation (CMA) of its antiviral drug remdesivir in the treatment of COVID-19, it has been revealed, with the agency looking to streamline its review process to approve the therapy for use as soon as possible.
10 – Coronavirus pandemic puts UK’s post-Brexit drug stockpile at risk
The pharmaceutical industry has warned the UK government that certain stockpiles of medicine have been used up due to the pandemic, according to the BBC.
Related Content
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application …
Pharmafile.com’s top 10 news stories of the week
Among our ten most-read stories this week: NICE has announced that more patients are eligible …
Pharmafile.com’s weekly COVID-19 news round-up
The past week has continued to see positive COVID-19 news; CytoDyn’s treatment for patients with …
